3 170

Cited 6 times in

Concurrent use of methotrexate and celecoxib increases risk of silent liver fibrosis in rheumatoid arthritis patients with subclinical reduced kidney function

DC FieldValueLanguage
dc.contributor.author박민찬-
dc.contributor.author박용범-
dc.contributor.author박진수-
dc.contributor.author이상원-
dc.contributor.author이수곤-
dc.date.accessioned2015-01-06T17:19:29Z-
dc.date.available2015-01-06T17:19:29Z-
dc.date.issued2014-
dc.identifier.issn0770-3198-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/99766-
dc.description.abstractWe evaluated the effects of concurrent use of methotrexate and celecoxib on silent liver and kidney damages in rheumatoid arthritis (RA) patients. We enrolled 92 RA patients with normal laboratory results related to liver and kidney functions, who had received methotrexate and celecoxib concurrently over 6 months. Liver stiffness measurement (LSM) using transient elastography and ultrasonography were performed along with blood and urine tests. Estimated glomerular filtration rate (eGFR) was calculated by both the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) and the Modification of Diet in Renal Disease (MDRD) equations. Initial eGFR represented kidney function at the time of the initiation of celecoxib. The cutoff for abnormal LSM values was adopted as 5.3 kPa. The optimal cutoff of each eGFR for abnormal LSM values was also calculated. The median age of patients was 55 years old (74 women). The median LSM was 4.4 kPa and the median eGFRs and median initial eGFRs ranged from 89 to 99 mL/min/1.73 m2. The cumulative doses of methotrexate and celecoxib and their concurrent administration duration did not affect LSM values and eGFRs. Both eGFRs were significantly associated with LSM values. Patients with initial eGFR(CKD-EPI), initial eGFR(MDRD), and eGFR(CKD-EPI) below each optimal cutoff had significantly high risks for silent liver fibrosis (RR 9.4, 10.3, and 4.4, p < 0.001, respectively). Both initial eGFRs (CKD-EPI and MDRD) and eGFR (CKD-EPI) were significant predictors for the development of silent liver fibrosis in RA patients who had received methotrexate and celecoxib concurrently for at least 6 months.-
dc.description.statementOfResponsibilityopen-
dc.format.extent1415~1423-
dc.relation.isPartOfCLINICAL RHEUMATOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAntirheumatic Agents/therapeutic use-
dc.subject.MESHArthritis, Rheumatoid/drug therapy*-
dc.subject.MESHArthritis, Rheumatoid/physiopathology-
dc.subject.MESHCelecoxib-
dc.subject.MESHCross-Sectional Studies-
dc.subject.MESHCyclooxygenase 2 Inhibitors/therapeutic use-
dc.subject.MESHDrug Therapy, Combination-
dc.subject.MESHFemale-
dc.subject.MESHGlomerular Filtration Rate/physiology-
dc.subject.MESHHumans-
dc.subject.MESHIncidence-
dc.subject.MESHKidney/physiopathology*-
dc.subject.MESHLiver Cirrhosis/chemically induced*-
dc.subject.MESHLiver Cirrhosis/epidemiology*-
dc.subject.MESHLiver Cirrhosis/physiopathology-
dc.subject.MESHMale-
dc.subject.MESHMethotrexate/therapeutic use*-
dc.subject.MESHMiddle Aged-
dc.subject.MESHMultivariate Analysis-
dc.subject.MESHPilot Projects-
dc.subject.MESHPyrazoles/therapeutic use*-
dc.subject.MESHRisk Factors-
dc.subject.MESHSulfonamides/therapeutic use*-
dc.subject.MESHTime Factors-
dc.subject.MESHTreatment Outcome-
dc.titleConcurrent use of methotrexate and celecoxib increases risk of silent liver fibrosis in rheumatoid arthritis patients with subclinical reduced kidney function-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학)-
dc.contributor.googleauthorJin Su Park-
dc.contributor.googleauthorMin-Chan Park-
dc.contributor.googleauthorYong-Beom Park-
dc.contributor.googleauthorSoo-Kon Lee-
dc.contributor.googleauthorSang-Won Lee-
dc.identifier.doi10.1007/s10067-014-2719-7-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA01470-
dc.contributor.localIdA01579-
dc.contributor.localIdA01698-
dc.contributor.localIdA02889-
dc.contributor.localIdA02824-
dc.relation.journalcodeJ00612-
dc.identifier.eissn1434-9949-
dc.identifier.pmid24941927-
dc.identifier.urlhttp://link.springer.com/article/10.1007%2Fs10067-014-2719-7-
dc.subject.keywordCelecoxib-
dc.subject.keywordEstimated glomerular filtration rate-
dc.subject.keywordLiver fibrosis-
dc.subject.keywordMethotrexate-
dc.subject.keywordRheumatoid arthritis-
dc.subject.keywordTransient elastography-
dc.contributor.alternativeNamePark, Min Chan-
dc.contributor.alternativeNamePark, Yong Beom-
dc.contributor.alternativeNamePark, Jin Su-
dc.contributor.alternativeNameLee, Sang Won-
dc.contributor.alternativeNameLee, Soo Kon-
dc.contributor.affiliatedAuthorPark, Min Chan-
dc.contributor.affiliatedAuthorPark, Yong Beom-
dc.contributor.affiliatedAuthorPark, Jin Su-
dc.contributor.affiliatedAuthorLee, Soo Kon-
dc.contributor.affiliatedAuthorLee, Sang Won-
dc.rights.accessRightsfree-
dc.citation.volume33-
dc.citation.number10-
dc.citation.startPage1415-
dc.citation.endPage1423-
dc.identifier.bibliographicCitationCLINICAL RHEUMATOLOGY, Vol.33(10) : 1415-1423, 2014-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.